Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase

SAN DIEGO, CA / ACCESSWIRE / December 11, 2018 / Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly, will be presenting at the Digital Medicine and MedTech Showcase 2019 on Tuesday, January 8 at 10:30am PST in San Francisco. Edward Cox, CEO of Dthera Sciences, will provide an update on the company’s upcoming milestones and strategy.

Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease. To the company’s knowledge, DTHR-ALZ is the first product to receive Breakthrough Device designation for the treatment of Alzheimer’s disease, and Dthera Sciences is only the second digital therapeutic company to receive this designation. If granted approval by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer’s disease.

The Digital Medicine and MedTech Showcase is held annually during the J.P. Morgan Healthcare Conference, the largest healthcare investment symposium in the industry. The J.P. Morgan Healthcare Conference is also one of the most active times for presenters to meet with pharmaceutical companies as potential partners. Dthera is pursuing a pharmaceutical partner for the commercialization of DTHR-ALZ.

About Digital Medicine and MedTech Showcase
Digital Medicine and MedTech Showcase is the dedicated home for the digital health and medtech communities devoted to providing private and public companies an opportunity to meet with investors and strategic partners during the J.P. Morgan Annual Health Conference, the industry’s largest and most established healthcare investor conference. See https://ebdgroup.knect365.com/biotech-showcase/ for more information on the Showcase.

About Dthera Sciences
Dthera Sciences (OTCQB: DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease. To the company’s knowledge, DTHR-ALZ is the first product to receive Breakthrough Device designation for the treatment of Alzheimer’s disease, and Dthera Sciences is only the second digital therapeutic company to receive this designation. If granted approval by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer’s disease. Please see www.dthera.com for more information.

Forward Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of therapeutic products and technologies, as well as the Company’s efforts to increase its customer base. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from the Company.

Contacts:
Geno Kostikov,
Corporate Development
geno@dthera.com
(858) 284-0880

Investor Relations
Marek Ciszewski, J.D.
Marek@Liolios.com
(949) 574-3860

SOURCE: Dthera Sciences

ReleaseID: 530238